Global Intra Uterine Contraceptive Devices Market Size By Type (Copper IUCD, Hormonal IUCD), By Application (Hospitals, Gynaecology Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Intra Uterine Contraceptive Devices (IUCD) Market was valued at USD 4.3 billion in 2023 and is projected to reach USD 7.6 billion by 2031, growing at a CAGR of 7.3% during the forecast period from 2023 to 2031. IUCDs are one of the most effective and long-acting forms of reversible contraception, increasingly preferred due to their high efficacy, low maintenance, and cost-effectiveness. Rising awareness of family planning, expanding government initiatives to control population growth, and increasing demand for non-hormonal contraceptive options are fueling market growth worldwide.

Drivers:

Rising Awareness and Government Initiatives

National and international health bodies are promoting awareness campaigns around birth control, with IUCDs being positioned as a safe and efficient choice. Governments in developing countries are subsidizing IUCD programs to curb unplanned pregnancies and manage population health, driving widespread adoption.

Increased Demand for Long-Acting Reversible Contraceptives (LARCs)

LARCs like IUCDs are increasingly preferred for their extended protection (up to 10 years), reversibility, and low user error compared to daily pills or short-term methods. This trend is pushing both usage rates and innovation in IUCD technologies.

Technological Innovations and Product Approvals

The development of hormone-releasing IUCDs that offer both contraceptive and therapeutic benefits, along with minimal side effects, is attracting new users. Approvals of innovative devices in Europe, North America, and Asia-Pacific are further propelling market expansion.

Restraints:

Risk of Side Effects and Misconceptions

Despite their effectiveness, concerns over potential side effects like irregular bleeding, discomfort, and infection continue to hinder adoption. In some regions, cultural and social stigma regarding contraceptive devices remains a major restraint.

Limited Access in Low-Income Settings

Infrastructure limitations and lack of trained healthcare professionals to administer IUCDs pose challenges in many low-income regions. These limitations restrict access and slow market penetration despite growing demand.

Opportunity:

Expanding Penetration in Emerging Markets

Emerging economies such as India, Brazil, and parts of Africa present significant opportunities due to unmet contraceptive needs, favorable government initiatives, and increasing investments in women’s reproductive health infrastructure.

Growing Popularity of Non-Hormonal and Biocompatible IUCDs

The demand for non-hormonal IUCDs is rising, especially among women sensitive to hormonal contraceptives. The development of copper-free, biodegradable, and bioinert devices can unlock new consumer segments and market opportunities.

Market by System Type Insights:

Hormonal IUCDs emerged as the leading segment in 2023, attributed to their dual functionality in contraception and menstrual regulation. Products like Mirena and Kyleena are widely accepted due to lower bleeding risk and added therapeutic benefits. However, Copper IUCDs are expected to witness strong growth due to their hormone-free nature and suitability for women avoiding systemic hormonal exposure.

Market by End-use Insights:

Hospitals and Gynecology Clinics held the largest market share in 2023, driven by the availability of skilled personnel and sterilized environments for device insertion. The Community Health Centers segment is expected to grow rapidly due to public health efforts in rural and underprivileged areas focusing on contraceptive education and services.

Market by Regional Insights:

Asia-Pacific dominated the global IUCD market in 2023, led by high population density, strong government support for family planning programs, and growing awareness. North America remains a strong market with advanced healthcare infrastructure and growing demand for hormonal IUCDs. Europe also contributes significantly due to widespread adoption and favorable reimbursement policies.

Competitive Scenario:

Key players in the Global Intra Uterine Contraceptive Devices Market include:

Bayer AG

CooperSurgical Inc.

Teva Pharmaceutical Industries Ltd.

Pregna International Ltd.

DKT International

OCON Healthcare

Meril Life Sciences

Medisafe Distribution Inc.

SMB Corporation

Egemen International

These companies focus on regulatory approvals, R&D investment, product diversification, and expansion into untapped regions. Strategic collaborations with health agencies and public-private partnerships are enhancing market reach.

Scope of Work – Global Intra Uterine Contraceptive Devices Market

Report Metric Details

Market Size (2023) USD 4.3 billion

Projected Market Size (2031) USD 7.6 billion

CAGR (2023–2031) 7.3%

Market Segments By System Type (Hormonal IUCDs, Copper IUCDs),

By End-use (Hospitals & Clinics, Community Health Centers)

Growth Drivers Government initiatives for birth control,

Rising demand for long-acting contraceptive methods,

Technological advancements in IUCD designs

Opportunities Expansion in emerging markets,

Rising demand for hormone-free and biocompatible devices

Key Market Developments:

2023: Bayer AG received extended FDA approval for its hormonal IUCD "Kyleena," targeting extended contraceptive duration up to 7 years.

2024: CooperSurgical launched a next-generation copper IUCD with improved biocompatibility and ease of insertion.

2025: Pregna International entered a strategic partnership with governments in Southeast Asia to scale IUCD access through community health programs.

FAQs:

What is the current market size of the Global Intra Uterine Contraceptive Devices Market?

The market was valued at USD 4.3 billion in 2023.

What is the major growth driver of the Global Intra Uterine Contraceptive Devices Market?

The major growth driver is the increasing adoption of long-acting reversible contraceptives supported by government initiatives.

Which is the largest region during the forecast period in the Global Intra Uterine Contraceptive Devices Market?

Asia-Pacific is expected to lead the market during the forecast period.

Which segment accounted for the largest market share in the Global Intra Uterine Contraceptive Devices Market?

Hormonal IUCDs accounted for the largest market share in 2023.

Who are the key market players in the Global Intra Uterine Contraceptive Devices Market?

Key players include Bayer AG, CooperSurgical, Teva Pharmaceuticals, Pregna International, and OCON Healthcare.